The effect of topical tretinoin 0.1% cream vs vehicle cream combined with narrowband UVB on vitiligo treatment: a randomized, double blind, half body control trial

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100044307

Enrollment

Unknown

Registered

2021-03-16

Start date

2021-04-01

Completion date

Unknown

Last updated

2021-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Interventions

Experimental group:Tretinoin 0.1% cream

Control group:placebo

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 year; 2. The patient participation will be voluntarily, and a written informed consent form will be signed; 3. Patient with generalized, stable vitiligo lesions bilateral and symmetrical in distribution (stable vitiligo; no new lesions for last 3 months); 4. There are at least two symmetrical depigmentry patches more than 2cm x 2cm in size.

Exclusion criteria

Exclusion criteria: 1. Patients with unstable vitiligo, acral vitiligo, and facial vitiligo; 2. Patients who has tendency for keloids or hypertrophy scars; 3. Patients who is pregnant and lactating; 4. Patients with severe autoimmune diseases(alopecia areata, diabetes, Addisions disease, systemic lupus erythematosus (SLE); 5. Patients did receive phototherapy for last month; 6. Patients who used topical drug (steroid, TCI, or photosensitive agents) in the past 2 weeks.

Design outcomes

Primary

Measure	Time frame
VASI scoring;	—

Countries

China

Contacts

Public ContactGao Xinghua

The First Affiliated Hospital of China Medical University

gaobarry@hotmail.com+86 13940152467

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026